2 Information about nivolumab

Marketing authorisation indication

Nivolumab (Opdivo, Bristol-Myers Squibb) as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of platinum-containing therapy.

Dosage in the marketing authorisation

3 mg/kg by intravenous infusion every 2 weeks.


£439 per 40‑mg vial or £1,097 per 100‑mg vial (excluding VAT; British national formulary online, accessed September 2017).

The company has a commercial arrangement, which would apply if the technology had been recommended.

  • National Institute for Health and Care Excellence (NICE)